RECOVERY & TISSUE REPAIR / COLOPHON
Contact the Editorial Desk
Correspondence on citations, corrections, and new research — the notes a literature file is most glad to receive.
Correspondence
Advantage Peptides is glad to hear about the research record itself: a citation quoted wrong, a newly published study on BPC-157 or its constituent peptides, or a regulatory change that moves an approval or scheduling status. Messages of that kind are the most useful ones this site gets, and each is read with care.
The submissions that move fastest name the page at issue, quote the exact passage being challenged, and attach the supporting reference — a PubMed identifier or full citation wherever it exists. In that shape a proposed fix can be traced back to its source before anything on the page changes.
Editorial mailbox: editors@advantagepeptides.com
What lies outside this remit
Because Advantage Peptides reads literature rather than running a clinic or selling a product, several things fall outside what it can do: it cannot advise on or endorse human use of any peptide named here; it cannot suggest a dose, schedule, or route for any individual; it cannot sell, source, or help you locate a compound from any supplier; and it cannot judge whether a cited result applies to one particular person.
None of BPC-157, GLOW, or KLOW is an approved medicine, and none is legally available as a human pharmaceutical. Readers looking for guidance on tissue repair, tendon or ligament recovery, or any related condition should bring that question to a licensed clinician. Anyone subject to anti-doping testing should note that some components here overlap with WADA-monitored substances. Replies to correspondence are not guaranteed and can be slow.